AKB 10108
Alternative Names: AKB-10108Latest Information Update: 07 Apr 2024
At a glance
- Originator Akebia Therapeutics
- Class
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Retinopathy of prematurity
Most Recent Events
- 14 Mar 2024 AKB 10108 is available for licensing as of 14 Mar 2024. https://akebia.com/partnering/ (Akebia Therapeutics website, March 2024)
- 31 Jan 2024 Preclinical trials in Retinopathy of prematurity in USA (unspecified route) prior to January 2024
- 31 Jan 2024 Pharmacodynamics data from a preclinical study in Retinopathy of prematurity released by Akebia Therapeutics